On Friday, Shares of Bristol-Myers Squibb Co (NYSE:BMY), added 0.09% and closed at $53.92 in the last trading session. The last trading range of the stock ranges between $53.90 and $54.37. Bristol-Myers Squibb Company (BMY) and Nektar Therapeutics (NKTR) recently declared a new clinical partnershipto evaluate Bristol-Myers Squibb’s Opdivo (nivolumab) with Nektar’s investigational medicine, NKTR-214, as a potential combination treatment regimen in five tumor types and seven potential indications. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and natural killer (NK) cells directly in the tumor micro-environment and increase expression of PD-1 on these immune cells.
“We are excited to explore the potential benefits in multiple types of cancer of the combination of Opdivo with Nektar’s innovative cancer immunotherapy,” said Fouad Namouni, M.D., Head of Oncology, Bristol-Myers Squibb. “We believe that a combination regimen which utilizes two different and complementary mechanisms designed to harness the body’s own immune system to fight cancer has the potential to provide new treatment options for patients.”
The Phase 1/2 clinical trials will evaluate the potential for the combination of Opdivo and NKTR-214 to show improved and sustained efficacy and tolerability above the current standard of care in melanoma, kidney, colorectal, bladder and non-small cell lung cancer patients. An initial dose-escalation trial is underway with Opdivo and NKTR-214.
Amyris Inc (NASDAQ:AMRS), jumped 14.99% and closed at $0.580 in the last trading session. The last trading range of the stock ranges between $0.54 and $0.61. The company’s Market capitalization is $156.74 Billion with the total Outstanding Shares of 235.02 Million. Amyris, Inc. (AMRS), the industrial bioscience company, recently declared that it has expanded its planned partnership with a global nutraceuticals market leader. The new agreement represents a noteworthyexpansion in expected revenue contrast to the prior agreement declared on April 27, 2016, and includes the addition of a new nutraceutical target, a credit line of up to $25 million with a 5-year maturity, and an option for a $5-million planned investment from one of the world’s leading nutraceuticals manufacturers.
Amyris has already started large shipments of farnesene as part of its earlier declared supply agreement with this partner, for which Amyris has become an essential part of its highly disruptive technology to capture market share. The partner is nearing completion of a dedicated manufacturing facility to convert Amyris’s farnesene and expand volume production over time.
This agreement and the related processing technology for the farnesene building block will facilitate a noteworthycost advantage within a large global market for what will now be two agreed on global products used daily by many for nutritional benefit. This is a noteworthyachievement consistent with Amyris’s mission to assist its customers do better while doing better for the planet. Demand for global nutritional products continues to grow at a much faster pace than GDP and supplying these products from sustainable sources at a lower cost than presently possible is critical for the growing population of the world.